Literature DB >> 16877359

Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Katharina Schindowski1, Alexis Bretteville, Karelle Leroy, Séverine Bégard, Jean-Pierre Brion, Malika Hamdane, Luc Buée.   

Abstract

Tau transgenic mice are valuable models to investigate the role of tau protein in Alzheimer's disease and other tauopathies. However, motor dysfunction and dystonic posture interfering with behavioral testing are the most common undesirable effects of tau transgenic mice. Therefore, we have generated a novel mouse model (THY-Tau22) that expresses human 4-repeat tau mutated at sites G272V and P301S under a Thy1.2-promotor, displaying tau pathology in the absence of any motor dysfunction. THY-Tau22 shows hyperphosphorylation of tau on several Alzheimer's disease-relevant tau epitopes (AT8, AT100, AT180, AT270, 12E8, tau-pSer396, and AP422), neurofibrillary tangle-like inclusions (Gallyas and MC1-positive) with rare ghost tangles and PHF-like filaments, as well as mild astrogliosis. These mice also display deficits in hippocampal synaptic transmission and impaired behavior characterized by increased anxiety, delayed learning from 3 months, and reduced spatial memory at 10 months. There are no signs of motor deficits or changes in motor activity at any age investigated. This mouse model therefore displays the main features of tau pathology and several of the pathophysiological disturbances observed during neurofibrillary degeneration. This model will serve as an experimental tool in future studies to investigate mechanisms underlying cognitive deficits during pathogenic tau aggregation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877359      PMCID: PMC1698785          DOI: 10.2353/ajpath.2006.060002

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  65 in total

1.  Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.

Authors:  T Ishihara; M Hong; B Zhang; Y Nakagawa; M K Lee; J Q Trojanowski; V M Lee
Journal:  Neuron       Date:  1999-11       Impact factor: 17.173

2.  Familial autosomal dominant cortico-basal degeneration with the P301S mutation in the tau gene: an example of phenotype variability.

Authors:  W Casseron; J P Azulay; E Guedj; J L Gastaut; J Pouget
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

3.  Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms.

Authors:  Cathy Andorfer; Christopher M Acker; Yvonne Kress; Patrick R Hof; Karen Duff; Peter Davies
Journal:  J Neurosci       Date:  2005-06-01       Impact factor: 6.167

4.  Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

Authors:  Martin Ramsden; Linda Kotilinek; Colleen Forster; Jennifer Paulson; Eileen McGowan; Karen SantaCruz; Aaron Guimaraes; Mei Yue; Jada Lewis; George Carlson; Michael Hutton; Karen H Ashe
Journal:  J Neurosci       Date:  2005-11-16       Impact factor: 6.167

5.  Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology.

Authors:  I F Bronner; B C ter Meulen; A Azmani; L A Severijnen; R Willemsen; W Kamphorst; R Ravid; P Heutink; J C van Swieten
Journal:  Brain       Date:  2005-07-13       Impact factor: 13.501

6.  FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation.

Authors:  A D Sperfeld; M B Collatz; H Baier; M Palmbach; A Storch; J Schwarz; K Tatsch; S Reske; M Joosse; P Heutink; A C Ludolph
Journal:  Ann Neurol       Date:  1999-11       Impact factor: 10.422

7.  Phenotypic heterogeneity within a new family with the MAPT p301s mutation.

Authors:  Minoru Yasuda; Yoshitsugu Nakamura; Toshio Kawamata; Hiroshi Kaneyuki; Kiyoshi Maeda; Osamu Komure
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

Review 8.  Alzheimer's disease: Abeta, tau and synaptic dysfunction.

Authors:  Frank M LaFerla; Salvatore Oddo
Journal:  Trends Mol Med       Date:  2005-04       Impact factor: 11.951

9.  Expression of reef coral fluorescent proteins in the central nervous system of transgenic mice.

Authors:  Petra G Hirrlinger; Anja Scheller; Christian Braun; Markus Quintela-Schneider; Babette Fuss; Johannes Hirrlinger; Frank Kirchhoff
Journal:  Mol Cell Neurosci       Date:  2005-11       Impact factor: 4.314

10.  Tau suppression in a neurodegenerative mouse model improves memory function.

Authors:  K Santacruz; J Lewis; T Spires; J Paulson; L Kotilinek; M Ingelsson; A Guimaraes; M DeTure; M Ramsden; E McGowan; C Forster; M Yue; J Orne; C Janus; A Mariash; M Kuskowski; B Hyman; M Hutton; K H Ashe
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

View more
  138 in total

1.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

2.  mTOR-mediated hyperphosphorylation of tau in the hippocampus is involved in cognitive deficits in streptozotocin-induced diabetic mice.

Authors:  Shan Wang; Shan-lei Zhou; Fang-yuan Min; Jin-ju Ma; Xia-jie Shi; Erika Bereczki; Jing Wu
Journal:  Metab Brain Dis       Date:  2014-03-30       Impact factor: 3.584

3.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Authors:  Laetitia Troquier; Raphaelle Caillierez; Sylvie Burnouf; Francisco J Fernandez-Gomez; Marie-Eve Grosjean; Nadege Zommer; Nicolas Sergeant; Susanna Schraen-Maschke; David Blum; Luc Buee
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

Review 4.  Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse models.

Authors:  Jennifer I Luebke; Christina M Weaver; Anne B Rocher; Alfredo Rodriguez; Johanna L Crimins; Dara L Dickstein; Susan L Wearne; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2010-02-24       Impact factor: 3.270

5.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 6.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

7.  Cortical and hippocampal neurons from truncated tau transgenic rat express multiple markers of neurodegeneration.

Authors:  Peter Filipcik; Martin Cente; Gabriela Krajciova; Ivo Vanicky; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

Review 8.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

Review 9.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

Review 10.  The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease.

Authors:  Johanna L Crimins; Amy Pooler; Manuela Polydoro; Jennifer I Luebke; Tara L Spires-Jones
Journal:  Ageing Res Rev       Date:  2013-03-22       Impact factor: 10.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.